INTRAVENOUS SOLUTIONS MARKET ANALYSIS

Intravenous Solutions Market, by Solution (Saline (Normal Saline (0.9% NaCl) and Hypertonic Saline), Dextran, Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and Trace Elements, and Mixed Solutions), by Bag Type (Large Volume Bags (greater than 250ml) and Small Volume Bags (less than 250ml)), by Application (Basic IV Solution, Nutritional IV Solution, Blood IV Solution, Drug IV Solution, and Irrigation IV Solution), by End User (Hospitals, Clinics, Ambulatory Surgery Centers, and Home Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Published In : Mar 2024
Code : CMI1134
Pages :215
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the only authorized IV formulation that targets and inhibits interleukin-17A (IL-17A), as well as the only non-tumor necrosis factor alpha (TNF-α) IV option accessible in all indications.
In February 2023, The U.S. FDA approved ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement treatment. ALTUVIIIO is recommended for regular prophylaxis and on-demand therapy to reduce bleeding episodes, as well as perioperative care (surgery) in adults and children with hemophilia A.
In June 2022, Breckenridge Pharmaceutical, Inc., a generic pharmaceutical manufacturing company, announced that the U.S. Food and Drug Administration (FDA) had granted approval for its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder. This product was developed in collaboration with Natco Pharma Limited, a multinational pharmaceutical company. Breckenridge received final approval for the 60mg/1.5mL (40mg/mL) strength.
In May 2022, SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that the U.S. FDA had approved an intravenous (IV) version of TPOXX for the treatment of smallpox. The IV formulation is a significant option for patients who are unable to take TPOXX's oral capsules.
In July 2021, Grifols, a prominent global supplier of plasma-derived pharmaceuticals, announced that it would establish an intravenous (IV) solutions manufacturing facility in Nigeria for Dozie and Dozie's Pharma Nig Ltd., a leading distributor of healthcare products in the Nigeria and surrounding regions. When finished in southeast Nigeria in 2024, the manufacturing installation's initial phase will produce up to 5.5 million intravenous solution bags per year for use in Nigerian and other African hospitals and healthcare facilities.
In December 2020, Royal Philips, a health technology company, announced that it had signed an agreement to acquire Vesper Medical Inc., a U.S.-based medical technology company that develops minimally-invasive peripheral vascular devices. Vesper Medical will further expand Philips portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease.